A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
Tateaki NaitoUchino JunjiToru KojimaYutaka MatanoKoichi MinatoKentaro TanakaTakuro MizukamiShinji AtagiTakashi HigashiguchiKei MuroTakayama KoichiJunji FuruseEiichiro MorishimaToru TakiguchiKazuo TamuraPublished in: Cancer (2022)
Anamorelin is a drug that stimulates appetite and promotes weight gain. This clinical trial was aimed at determining its efficacy and safety in Japanese cancer patients with a low body mass index and cachexia, a syndrome associated with anorexia and weight loss. Anamorelin was found to improve body weight and anorexia-related symptoms in these patients, and these effects were durable for up to 24 weeks. Moreover, anamorelin was generally well tolerated. These findings suggest that anamorelin is a valuable treatment option for patients with cancer cachexia and a low body mass index.
Keyphrases
- body mass index
- weight gain
- weight loss
- body weight
- clinical trial
- open label
- birth weight
- end stage renal disease
- bariatric surgery
- ejection fraction
- chronic kidney disease
- roux en y gastric bypass
- phase ii
- papillary thyroid
- newly diagnosed
- double blind
- phase iii
- gastric bypass
- type diabetes
- randomized controlled trial
- study protocol
- combination therapy
- squamous cell
- adipose tissue
- phase ii study
- insulin resistance
- smoking cessation
- obese patients